Proqr Therapeutics Bv Stock Performance
| PRQR Stock | USD 2.42 0.15 6.61% |
The company holds a Beta of -0.66, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ProQR Therapeutics are expected to decrease at a much lower rate. During the bear market, ProQR Therapeutics is likely to outperform the market. At this point, ProQR Therapeutics has a negative expected return of -0.57%. Please make sure to check ProQR Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if ProQR Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ProQR Therapeutics BV has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 6.61 | Five Day Return 9.01 | Year To Date Return (11.68) | Ten Year Return (85.87) | All Time Return (83.57) |
1 | ProQR Therapeutics Highlights Q3 2024 Financial Results - TipRanks | 11/20/2024 |
2 | ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist | 12/10/2024 |
3 | ProQR Therapeutics Announces 8.1 Million in New Funding from Rett Syndrome Research Trust to ... | 12/11/2024 |
4 | ProQR Therapeutics SWOT analysis RNA-editing stock poised for clinical leap | 12/17/2024 |
5 | ProQR Therapeutics Receives Consensus Rating of Buy from Analysts | 01/13/2025 |
6 | Ballentine Partners LLC Takes Position in ProQR Therapeutics - Defense World | 01/27/2025 |
7 | ProQR Therapeutics N.V.s largest shareholders are individual investors with 60 percent ownership, institutions own 17 | 02/11/2025 |
| Begin Period Cash Flow | 94.8 M |
ProQR |
ProQR Therapeutics Relative Risk vs. Return Landscape
If you would invest 367.00 in ProQR Therapeutics BV on November 20, 2024 and sell it today you would lose (125.00) from holding ProQR Therapeutics BV or give up 34.06% of portfolio value over 90 days. ProQR Therapeutics BV is currently does not generate positive expected returns and assumes 5.2717% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than ProQR, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProQR Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProQR Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProQR Therapeutics BV, and traders can use it to determine the average amount a ProQR Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1075
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRQR |
Estimated Market Risk
| 5.27 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ProQR Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProQR Therapeutics by adding ProQR Therapeutics to a well-diversified portfolio.
ProQR Therapeutics Fundamentals Growth
ProQR Stock prices reflect investors' perceptions of the future prospects and financial health of ProQR Therapeutics, and ProQR Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProQR Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.30) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 180.98 M | ||||
| Shares Outstanding | 105.91 M | ||||
| Price To Earning | (1.97) X | ||||
| Price To Book | 9.87 X | ||||
| Price To Sales | 13.94 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 18.39 M | ||||
| EBITDA | (24.1 M) | ||||
| Net Income | (27.54 M) | ||||
| Cash And Equivalents | 156.4 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 19.73 M | ||||
| Debt To Equity | 0.70 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | 21.55 M | ||||
| Earnings Per Share | (0.31) X | ||||
| Market Capitalization | 256.29 M | ||||
| Total Asset | 137.88 M | ||||
| Retained Earnings | (400.85 M) | ||||
| Working Capital | 86.78 M | ||||
| Current Asset | 97.77 M | ||||
| Current Liabilities | 5.49 M | ||||
About ProQR Therapeutics Performance
Assessing ProQR Therapeutics' fundamental ratios provides investors with valuable insights into ProQR Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ProQR Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.16 | 1.11 | |
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.28) | (0.29) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.78) | (0.74) |
Things to note about ProQR Therapeutics performance evaluation
Checking the ongoing alerts about ProQR Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProQR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.51 M. Net Loss for the year was (27.54 M) with profit before overhead, payroll, taxes, and interest of 18.39 M. | |
| ProQR Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: ProQR Therapeutics N.V.s largest shareholders are individual investors with 60 percent ownership, institutions own 17 |
- Analyzing ProQR Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProQR Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ProQR Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProQR Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProQR Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProQR Therapeutics' stock. These opinions can provide insight into ProQR Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.